Memory and Insulin in Early Alzheimer's Disease (MAIN)

This study has been completed.
Information provided by (Responsible Party):
Jeff Burns, MD, University of Kansas Medical Center Research Institute Identifier:
First received: December 19, 2007
Last updated: June 22, 2012
Last verified: June 2012

To determine which parts of the brain are involved in insulin-related memory improvement in early Alzheimer's disease

Condition Intervention Phase
Alzheimer's Disease
Drug: Insulin Aspart
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Diagnostic
Official Title: Intranasal Insulin and Memory in Early Alzheimer's Disease

Resource links provided by NLM:

Further study details as provided by University of Kansas:

Primary Outcome Measures:
  • fMRI activation [ Time Frame: 2 Hours ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Cognitive testing [ Time Frame: 2 Hours ] [ Designated as safety issue: No ]

Enrollment: 30
Study Start Date: October 2007
Study Completion Date: May 2012
Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: Insulin Aspart
40IU insulin aspart applied intranasally
Placebo Comparator: 2 Drug: Placebo

Detailed Description:

Functional MRI study to characterize the neuroanatomic correlates of acute exogenous insulin-related improvements in cognitive performance in early Alzheimer's disease. The role of the apoE-e4 allele in modulating brain insulin responses is also addressed.


Ages Eligible for Study:   60 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Patients with Early Alzheimer's disease

Exclusion Criteria:

  • Patients with Late Alzheimer's disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00581867

United States, Kansas
University of Kansas Medical Center, Hoglund Brain Imaging Center
Kansas City, Kansas, United States, 66160
Sponsors and Collaborators
Jeff Burns, MD
Principal Investigator: Jeffrey M Burns, MD University of Kansas
  More Information

No publications provided

Responsible Party: Jeff Burns, MD, Assistant Professor, Director of the Alzheimer & Memory Center & AD Clinical Research Program, University of Kansas Medical Center Research Institute Identifier: NCT00581867     History of Changes
Other Study ID Numbers: 10896
Study First Received: December 19, 2007
Last Updated: June 22, 2012
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Nervous System Diseases
Neurodegenerative Diseases
Insulin Aspart
Hypoglycemic Agents
Pharmacologic Actions
Physiological Effects of Drugs processed this record on May 21, 2015